Related Experiment Videos
Neonatal rotavirus vaccination with RIT 4237 bovine rotavirus vaccine: a preliminary report
Insights
Neonatal rotavirus vaccination with RIT 4237 bovine rotavirus vaccine did not prevent rotavirus infection in infants. However, the vaccine appeared to reduce the severity of rotavirus gastroenteritis in the vaccinated group.
Area of Science:
- Pediatrics
- Infectious Diseases
- Vaccinology
Background:
- Rotavirus is a leading cause of severe gastroenteritis in infants globally.
- Oral rotavirus vaccines are being developed to prevent rotavirus infections.
- The RIT 4237 bovine rotavirus vaccine is an oral vaccine candidate.
Purpose of the Study:
- To evaluate the efficacy and safety of the RIT 4237 bovine rotavirus vaccine in newborn infants.
- To assess the vaccine's impact on rotavirus infection rates and gastroenteritis severity.
Main Methods:
- A randomized, placebo-controlled trial involving 244 newborn infants.
- Oral administration of RIT 4237 vaccine or placebo.
- Serological monitoring using enzyme-linked immunosorbent assay (ELISA) for immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies.
- Clinical follow-up for rotavirus gastroenteritis episodes over 16 months.
Main Results:
- Higher seroconversion rates (IgM) were observed in vaccine recipients initially.
- Rotavirus-seropositive rates (IgG) were significantly higher in vaccinated infants after the first season (55% vs. 37%).
- No significant difference in the number of rotavirus gastroenteritis episodes between groups (14 vs. 10).
- Vaccine recipients experienced significantly less severe gastroenteritis (1 severe episode) compared to placebo recipients (7 severe episodes).
Conclusions:
- Neonatal rotavirus vaccination with RIT 4237 vaccine did not provide protection against rotavirus infection.
- The RIT 4237 vaccine demonstrated a capacity to modify the severity of rotavirus gastroenteritis.
- Further research is needed to optimize rotavirus vaccine strategies for infant protection.
Abstract:
We vaccinated 244 newborn infants orally with RIT 4237 bovine rotavirus vaccine or placebo and followed them serologically and clinically for 16 months. Initially 39 of the 119 (33%) vaccine recipients compared with 1 of the 120 placebo recipients seroconverted by enzyme-linked immunosorbent assay-immunoglobulin M. After the first winter rotavirus season, at 7 months of age 55% of the vaccinated infants and 37% of the unvaccinated infants were rotavirus-seropositive by enzyme-linked immunosorbent assay-immunoglobulin G (P less than 0.01, chi square test). At 12 months of age, after a low rotavirus prevalence season, 34% of the vaccinated children and 23% of the unvaccinated children remained seropositive. There were 14 confirmed episodes of rotavirus gastroenteritis in the vaccine group and 10 episodes in the placebo group during the first 16 months. However, only 1 of the episodes in the vaccine group was severe, 4 were moderately severe and 9 were mild, whereas 7 episodes in the placebo group were severe and 3 were moderately severe (P less than 0.001 between groups, Fisher's exact test). There was no clear correlation between vaccine-induced clinical protection and initial serologic response (enzyme-linked immunosorbent assay-immunoglobulin M) to vaccination, but during follow-up severe rotavirus gastroenteritis was more likely to occur in children with no serum rotavirus immunoglobulin G antibody at the time of infection. We conclude at the present stage that neonatal rotavirus vaccination with RIT 4237 vaccine gives no protection against rotavirus infection but appears to modify the severity of gastroenteritis.